Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06254326 · ClinicalTrials.gov registry record · Phase 1
ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients
A Phase 1 study of Recurrent Oligodendroglioma and Progressive Oligodendroglioma, sponsored by University of Florida.
- Active
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06254326 is a Phase 1 study of Recurrent Oligodendroglioma and Progressive Oligodendroglioma that is active but no longer recruiting, run by University of Florida. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06254326, a Phase 1 study of Recurrent Oligodendroglioma and Progressive Oligodendroglioma, is active but no longer recruiting, sponsored by University of Florida.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will enroll 6 DLT evaluable subjects (up to 12 patients total) where we will evaluate feasibility and safety of adoptive cellular therapy combined with IDH1/2 inhibitors in patients with recurrent or progressive oligodendroglioma WHO grade 2 and WHO grade 3.
Conditions Studied
Interventions
- BIOLOGICAL TTRNA-DC vaccines with GM-CSF
- BIOLOGICAL TTRNA-xALT
- DRUG Td vaccine
- BIOLOGICAL Autologous Hematopoietic Stem cells (HSCs)
Study Locations (1)
Florida
- University of Florida Health Shands Hospital - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-09-19 |
| Est. Completion | 2028-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06254326
The ClinicalTrials.gov registry entry for NCT06254326 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Recurrent Oligodendroglioma appearing as the primary indexed condition, and to 4 interventions - of which TTRNA-DC vaccines with GM-CSF is the first listed.
NCT06254326 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06254326 about?
NCT06254326 is a clinical study titled "ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients". This study will enroll 6 DLT evaluable subjects (up to 12 patients total) where we will evaluate feasibility and safety of adoptive cellular therapy combined with IDH1/2 inhibitors in patients with recurrent or progressive oligodendroglioma WHO grade 2 and WHO grade 3.
What is the current status of trial NCT06254326?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-09-19. Estimated completion is 2028-06.
What conditions does trial NCT06254326 study?
This clinical trial studies the following conditions: Recurrent Oligodendroglioma, Progressive Oligodendroglioma.
What interventions are being tested in trial NCT06254326?
The interventions under investigation include: TTRNA-DC vaccines with GM-CSF (BIOLOGICAL), TTRNA-xALT (BIOLOGICAL), Td vaccine (DRUG), Autologous Hematopoietic Stem cells (HSCs) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06254326?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06254326 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.